Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 201

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 201
---
121,589
        )

        Share-based compensation expense(4)

        (17,999
        )

        (23,892
        )

        (13,586
        )

        (55,477
        )

        Restructuring expense(5)

        —

        —

        (2,023
        )

        (2,023
        )

        Depreciation and amortization expense

        (6,642
        )

        (12,294
        )

        (1,984
        )

        (20,920
        )

        Interest expense(6)

        —

        —

        (4,238
        )

        (4,238
        )

        Interest and other income, net

        —

        —

        4,056

        4,056

        Net loss attributable to Adaptive Biotechnologies Corporation

        (200,191
        )

        Net loss attributable to noncontrolling interest

        (177
        )

        Net loss

        $
        (200,368
        )
       
       (1) Includes MRD impairment of long-lived assets expenses. (2) Adjusted EBITDA is a non-GAAP financial measure. See “Management's Discussion and Analysis of Financial Condition and Results of Operations—Adjusted EBITDA” for an explanation of how it is calculated and used by management.(3) Includes all Immune Medicine operating expenses, other than research and development expenses. (4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, Equity Incentive Plans for details on our share-based compensation expense.(5) Represents expenses recognized in conjunction with restructuring activities. See Note 15, Restructurings for details on our restructuring expenses.(6) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, Revenue Interest Purchase Agreement for details on the Purchase Agreement.(7) Represents impairment costs for certain right-of-use and related long-lived assets. See Note 10, Leases for details on our impairment expense.

120

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Not applicable.

Item 9A. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we evaluated the effectiveness of the design and operation of our disclosure